CAPR Stock — Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (CAPR)

Updated October 16, 2026.

CAPR is a Stock. Total return is 31.6% over the past 24.3 years, 1043.9 points behind SPY at 1075.5%.

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics, with its lead candidate Deramiocel in phase 3 trials for Duchenne muscular dystrophy and additional programs in earlier development stages for vaccines and other disease applications. The company does not currently distribute to shareholders. This security appeals primarily to growth-oriented investors with high risk tolerance, as it is a pre-revenue biotech firm dependent on clinical trial success and regulatory approval.

CAPR performance versus SPY

Price and return data through 2026-10-16.

Total return is 31.6% over the past 24.3 years, 1043.9 points behind SPY at 1075.5%. Over the past year its total return — price change plus distributions reinvested — is 8.9%. Its deepest 1-year drawdown was 89.1%.

CAPR key facts

Asset type

Stock

Asset class

Equity

Inception date

06/20/2002

Distribution frequency

None

Last close

$6.71 (as of 2026-10-16)

Market cap

$390,112,616

Average volume

1920127.0

Payment date

06/05/2019

Beta

0.606

Payout ratio

0.0%

Forward P/E

78.7402

EPS

$-2.44

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CAPR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 89.1%.

Who may consider CAPR — and who may not

It is a weaker fit for investors who need monthly cash flow (CAPR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CAPR

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions